To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Alpha emitter radium-223 … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Alpha emitter radium-223 and survival in metastatic prostate cancer.

Journal article
Authors C Parker
S Nilsson
D Heinrich
S I Helle
J M O'Sullivan
S D Fosså
A Chodacki
P Wiechno
J Logue
M Seke
A Widmark
D C Johannessen
P Hoskin
D Bottomley
N D James
A Solberg
I Syndikus
J Kliment
S Wedel
S Boehmer
M Dall'Oglio
L Franzén
R Coleman
N J Vogelzang
C G O'Bryan-Tear
K Staudacher
J Garcia-Vargas
M Shan
Ø S Bruland
O Sartor
Jon Kindblom
Published in The New England journal of medicine
Volume 369
Issue 3
Pages 213-23
ISSN 1533-4406
Publication year 2013
Published at
Pages 213-23
Language en
Keywords Aged, Aged, 80 and over, Bone Neoplasms, mortality, radiotherapy, secondary, Double-Blind Method, Humans, Isotopes, Kaplan-Meier Estimate, Male, Middle Aged, Prostatic Neoplasms, mortality, pathology, radiotherapy, Radium, adverse effects, therapeutic use
Subject categories Cancer and Oncology

Abstract

Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?